一种新型甲型流感病毒交叉免疫抗原疫苗平台

IF 1.7 4区医学 Q3 PHARMACOLOGY & PHARMACY

Biological & pharmaceutical bulletin Pub Date : 2024-01-01 DOI:10.1248/bpb.b24-00337

Kenji Sekikawa, Haniyeh Bidadi, Miki Maeda, Liat Fux, Yakir Nataf, Hirofumi Komatsubara, Yutaka Komiyama, Osamu Kobayashi

{"title":"一种新型甲型流感病毒交叉免疫抗原疫苗平台","authors":"Kenji Sekikawa, Haniyeh Bidadi, Miki Maeda, Liat Fux, Yakir Nataf, Hirofumi Komatsubara, Yutaka Komiyama, Osamu Kobayashi","doi":"10.1248/bpb.b24-00337","DOIUrl":null,"url":null,"abstract":"We have developed a novel cross-immune antigen vaccine platform for influenza A virus. The vaccine antigen is a fusion protein of headless hemagglutinin (HA) and matrix protein 1 (M1), which possess B-cell and T-cell epitopes, respectively, that are conserved among subgroup A viruses. The single molecule of headless HA and M1 fusion protein forms an oligomer by self-assembly of M1. T-Helper 1 (Th1) and Th2 cells were activated in an antigen-specific manner in lymphocyte cultures of antigen-immunized mice. The antigen-immunized antiserum neutralized influenza virus A subtypes H1N1 and H3N2, and intranasal administration of the antigen reduced mortality to less than 30% in a protection assay.","PeriodicalId":8955,"journal":{"name":"Biological & pharmaceutical bulletin","volume":"47 12","pages":"2028-2031"},"PeriodicalIF":1.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Novel Cross-Immune Antigen Vaccine Platform for Influenza Virus Type A.\",\"authors\":\"Kenji Sekikawa, Haniyeh Bidadi, Miki Maeda, Liat Fux, Yakir Nataf, Hirofumi Komatsubara, Yutaka Komiyama, Osamu Kobayashi\",\"doi\":\"10.1248/bpb.b24-00337\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We have developed a novel cross-immune antigen vaccine platform for influenza A virus. The vaccine antigen is a fusion protein of headless hemagglutinin (HA) and matrix protein 1 (M1), which possess B-cell and T-cell epitopes, respectively, that are conserved among subgroup A viruses. The single molecule of headless HA and M1 fusion protein forms an oligomer by self-assembly of M1. T-Helper 1 (Th1) and Th2 cells were activated in an antigen-specific manner in lymphocyte cultures of antigen-immunized mice. The antigen-immunized antiserum neutralized influenza virus A subtypes H1N1 and H3N2, and intranasal administration of the antigen reduced mortality to less than 30% in a protection assay.\",\"PeriodicalId\":8955,\"journal\":{\"name\":\"Biological & pharmaceutical bulletin\",\"volume\":\"47 12\",\"pages\":\"2028-2031\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biological & pharmaceutical bulletin\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1248/bpb.b24-00337\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biological & pharmaceutical bulletin","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1248/bpb.b24-00337","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

我们开发了一种新型甲型流感病毒交叉免疫抗原疫苗平台。疫苗抗原是一种无头血凝素（HA）和基质蛋白1 （M1）的融合蛋白，它们分别具有在a亚群病毒中保守的b细胞和t细胞表位。无头HA与M1融合蛋白单分子通过M1的自组装形成寡聚物。在抗原免疫小鼠淋巴细胞培养中，t -辅助性细胞1 （Th1）和Th2细胞以抗原特异性的方式被激活。抗原免疫的抗血清中和了流感病毒A亚型H1N1和H3N2，在保护试验中，经鼻注射抗原可将死亡率降低到30%以下。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A Novel Cross-Immune Antigen Vaccine Platform for Influenza Virus Type A.

We have developed a novel cross-immune antigen vaccine platform for influenza A virus. The vaccine antigen is a fusion protein of headless hemagglutinin (HA) and matrix protein 1 (M1), which possess B-cell and T-cell epitopes, respectively, that are conserved among subgroup A viruses. The single molecule of headless HA and M1 fusion protein forms an oligomer by self-assembly of M1. T-Helper 1 (Th1) and Th2 cells were activated in an antigen-specific manner in lymphocyte cultures of antigen-immunized mice. The antigen-immunized antiserum neutralized influenza virus A subtypes H1N1 and H3N2, and intranasal administration of the antigen reduced mortality to less than 30% in a protection assay.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Biological & pharmaceutical bulletin 医学-药学

CiteScore

3.50

自引率

5.00%

发文量

247

审稿时长

2 months

期刊介绍： Biological and Pharmaceutical Bulletin (Biol. Pharm. Bull.) began publication in 1978 as the Journal of Pharmacobio-Dynamics. It covers various biological topics in the pharmaceutical and health sciences. A fourth Society journal, the Journal of Health Science, was merged with Biol. Pharm. Bull. in 2012. The main aim of the Society’s journals is to advance the pharmaceutical sciences with research reports, information exchange, and high-quality discussion. The average review time for articles submitted to the journals is around one month for first decision. The complete texts of all of the Society’s journals can be freely accessed through J-STAGE. The Society’s editorial committee hopes that the content of its journals will be useful to your research, and also invites you to submit your own work to the journals.